# EDGAR Filing Document

**Accession Number:** 0001841387
**File Stem:** 0001193125-25-184067
**Filing Date:** 2025-8
**Character Count:** 2695
**Document Hash:** df1b3b07f671cbb68ee4d7dabbfc140e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-184067.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0001193125-25-184067

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250820

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Candel Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001841387
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 522214851
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 117 KENDRICK STREET
- **STREET 2:** SUITE 450
- **CITY:** NEEDHAM
- **STATE:** MA
- **ZIP:** 02494
- **BUSINESS PHONE:** 617-916-5445

**MAIL ADDRESS:**
- **STREET 1:** 117 KENDRICK STREET
- **STREET 2:** SUITE 450
- **CITY:** NEEDHAM
- **STATE:** MA
- **ZIP:** 02494

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Candel Therapeutics, Inic.
- **DATE OF NAME CHANGE:** 20210120

**<u>VIA EDGAR</u>**

August 20, 2025

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Candel Therapeutics, Inc.**  |

---

**Acceleration Request for Registration Statement on Form S-3** 

**Filed August 14, 2025** 

**File No. 333-289595** 

Ladies and Gentlemen,

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Candel Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to August 22, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Finn Murphy at (212) 459-7257.

If you have any questions regarding this request, please contact William D. Collins of Goodwin Procter LLP at (617) 570-1447 or Finn Murphy at (212) 459-7257.

---

| |
|:---|
| Sincerely, |
| CANDEL THERAPEUTICS, INC. |
| /s/ Paul Peter Tak |
| Paul Peter Tak, M.D., Ph.D., FMedSci |
| President and Chief Executive Officer |

---

cc: Charles Schoch, *Candel Therapeutics, Inc.*

William D. Collins, Esq., *Goodwin Procter LLP*

Finnbarr D. Murphy, Esq., *Goodwin Procter LLP*